TheraRadar

Biosplice

Pre-Approval PRO BETA
🔴

Stale Activity

No new clinical trials started in 2+ years. Activity may be declining or company may be focusing on existing programs. Last trial started: 11/18/2022

20
Total Trials
6
Phase 3
7
Phase 2
0
Recruiting
170
Score

Pipeline by Phase

Phase 3
6
Phase 2
7
Phase 1
8

Therapeutic Focus

Knee Osteoarthritis Androgenetic Alopecia Colorectal Cancer Tendinopathy Osteoarthritis of the Knee

Clinical Trials (20)

NCT04931667 Phase 3 TERMINATED

3-year, Open-Label Study Evaluating Safety, Tolerability, and Efficacy of Lorecivivint in Knee Osteoarthritis

Started: 7/15/2021

NCT04520607 Phase 3 TERMINATED

A Long-Term Safety and Efficacy Study of Lorecivivint in Subjects With Osteoarthritis of the Knee

Started: 8/25/2020

NCT03928184 Phase 3 COMPLETED

Patient-Reported and Radiographic Outcomes in Evaluating Lorecivivint (SM04690) for the Treatment of Knee Osteoarthritis

Started: 5/17/2019

NCT04385303 Phase 3 COMPLETED

Patient-Reported Outcomes in Evaluating Lorecivivint (SM04690) for Moderate to Severe Knee Osteoarthritis (STRIDES-1)

Started: 5/26/2020

NCT05603754 Phase 3 COMPLETED

A Study Utilizing Patient-Reported Outcomes to Evaluate the Safety and Efficacy of Lorecivivint (SM04690) for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis (STRIDES)

Started: 11/18/2022

NCT03706521 Phase 2 TERMINATED

MRI Study to Evaluate the Safety and Efficacy of SM04690 for Knee Osteoarthritis

Started: 3/11/2019

NCT03727022 Phase 2 COMPLETED

Safety and Bone Health Study of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis

Started: 11/28/2018

NCT03742518 Phase 2 COMPLETED

A Study Evaluating the Efficacy and Safety of SM04554 Topical Solution in Male Subjects With Androgenetic Alopecia

Started: 11/1/2018

NCT03122860 Phase 2 COMPLETED

A Study Evaluating the Safety and Efficacy of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis

Started: 4/24/2017

NCT02536833 Phase 2 COMPLETED

A Study Evaluating the Safety, Tolerability, and Efficacy of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects

Started: 9/9/2015

NCT02275351 Phase 2 COMPLETED

A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)

Started: 11/1/2014

NCT02503137 Phase 2 COMPLETED

A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing

Started: 8/1/2015

NCT03355066 Phase 1 TERMINATED

A Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors

Started: 11/6/2017

NCT05084859 Phase 1 TERMINATED

A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors

Started: 11/3/2021

NCT04598542 Phase 1 COMPLETED

Drug-Drug Interaction Study of Lorecivivint and Triamcinolone Acetonide in Healthy Volunteers

Started: 10/13/2020

NCT03246399 Phase 1 TERMINATED

A Study of the Safety, Tolerability, and Pharmacokinetics of SM04690 Injectable Suspension Following Single Intradiscal Injection in Subjects With Degenerative Disc Disease

Started: 7/26/2017

NCT02191761 Phase 1 COMPLETED

Safety and Pharmacokinetics of SM04755 in Subjects With Advanced Colorectal, Gastric, Hepatic, or Pancreatic Cancer

Started: 6/19/2014

NCT03502434 Phase 1 COMPLETED

A Repeat Insult Patch Test (RIPT) Study Evaluating the Sensitization Potential of Topical SM04755 Solution in Healthy Volunteers

Started: 9/11/2017

NCT03229291 Phase 1 COMPLETED

A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of SM04755 Following Topical Administration to Healthy Subjects

Started: 11/3/2016

NCT02095548 Phase 1 COMPLETED

Phase 1, Dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SM04690 in Moderate to Severe Knee Osteoarthritis (OA)

Started: 3/1/2014

Drug Candidates

Lorecivivint Placebo lorecivivint SM04690 SM08502 Abiraterone Prednisone Docetaxel FOLFIRI Protocol Panitumumab
Activity Status: Stale
Last Trial Started: 11/18/2022
Last Trial Ended: 2/20/2024
Trials (12 months): 0
Completed Trials: 14
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.